Pharsight

Lamictal Odt patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7919115 GLAXOSMITHKLINE LLC Orally disintegrating tablet compositions of lamotrigine
Jan, 2029

(5 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8840925 GLAXOSMITHKLINE LLC Orally disintegrating tablet compositions of lamotrigine
Jul, 2028

(4 years from now)

US9339504 GLAXOSMITHKLINE LLC Orally disintegrating tablet compositions of lamotrigine
Jul, 2028

(4 years from now)

Lamictal Odt is owned by Glaxosmithkline Llc.

Lamictal Odt contains Lamotrigine.

Lamictal Odt has a total of 3 drug patents out of which 0 drug patents have expired.

Lamictal Odt was authorised for market use on 08 May, 2009.

Lamictal Odt is available in tablet, orally disintegrating;oral dosage forms.

Lamictal Odt can be used as lamictal is an antiepileptic drug (aed) indicated for: epilepsy-adjunctive therapy in patients greater than or equal to 2 years of age: (1.1) partial seizures primary generalized tonic-clonic seizures.

The generics of Lamictal Odt are possible to be released after 04 January, 2029.

Drugs and Companies using LAMOTRIGINE ingredient

Market Authorisation Date: 08 May, 2009

Treatment: Lamictal is an antiepileptic drug (aed) indicated for: epilepsy-adjunctive therapy in patients greater than or equal to 2 years of age: (1.1) partial seizures primary generalized tonic-clonic seizures

Dosage: TABLET, ORALLY DISINTEGRATING;ORAL

How can I launch a generic of LAMICTAL ODT before it's drug patent expiration?
More Information on Dosage

LAMICTAL ODT family patents

Family Patents

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic